Balance of ‘stop’ and ‘go’ signaling could be key to cancer immunotherapy
A Penn study shows potential of the interferon pathway as a biomarker to help predict which patients are likely to respond to immunotherapies.
Elderly patients with metastatic renal cell carcinoma benefit from targeted therapies
A Penn study of Medicare patients who are often underrepresented in medical trials finds overall survival benefits from treatment with targeted therapies.
How to reinvigorate exhausted immune cells to stop cancer
A Penn study has identified a protein called TOX that regulates exhausted T-cells, and could be a key to new immunotherapies.
For melanoma patients, one dose of immunotherapy before surgery can lead to remission
An Abramson Cancer Center study finds that with a single dose of a PD-1 inhibitor, immune responses can peak in just one week.
Immune profiling: A new opportunity for drug development
Immunologists, oncologists, and infectious disease specialists are thinking about the immune system in a new way based on its integral and ubiquitous ties to human health, amassing data on its role in gastroenterology, neurology, cardiovascular disease, and metabolic disease.
The ‘immunorevolution’ has begun
Penn Medicine experts gathered for a panel discussion about their innovative new approach to harness the body’s own immune system to fight cancer.
Abramson Cancer Center receives $10.7 million to study CAR T cells in solid tumors
A new program project grant from the National Cancer Institute (NCI) will fund research by the Translational Center of Excellence for Lung Cancer Immunology for experimental approaches in lung cancer and mesothelioma.
Discovering a single cell that leads to relapse
Research from the Abramson Cancer Center identified a single leukemic cell, engineered for CAR T therapy, that caused a deadly recurrence of pediatric B-cell acute lymphoblastic leukemia.
CAR T cell therapy receives approval for use across European Union
The European Commission has approved a personalized cellular therapy developed at the Abramson Cancer Center, making it the first CAR T cell therapy permitted for use in the European Union in two distinct indications.
Cancer cells send out ‘drones’ to battle the immune system from afar
Checkpoint inhibitor therapies have made metastatic melanoma and other cancers a survivable condition, but only for some patients. Researchers uncovered a novel mechanism by which tumors suppress the immune system, raising the possibility that a straightforward blood test could predict which patients could respond to immunotherapy.